The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Andrea Tan - The Goldman Sachs Group, Inc. - Analyst
: Yes, of course. Michael, maybe I'll start with you here. As you think about the last 12 months, Precision has gone through a strategic transition and
one that has now put you squarely on path to be an in vivo gene-editing company, and that's where your priority is. Maybe speak to us about what
drove that decision. What has that meant to Precision as a company?
Question: Andrea Tan - The Goldman Sachs Group, Inc. - Analyst
: Jeff, maybe I can turn it over to you before we dig into the programs here. But as Michael alluded to, the ARCUS platform, help us understand how
that is differentiated from other gene-editing technologies.
Question: Andrea Tan - The Goldman Sachs Group, Inc. - Analyst
: Maybe one follow up there. As the landscape has changed, there's been the next wave of editing technologies that have come about, whether it's
base editing, prime editing, epigenetic editing, how all of these approaches coexist. And there are a number of these companies that are using
these different types of technologies but going after the same indications. How do you think about the interplay of all of these?
Question: Andrea Tan - The Goldman Sachs Group, Inc. - Analyst
: Maybe one last follow up there. Since you referenced the FDA getting comfortable around the safety profile, what are you seeing? And maybe
describe to us the extent of the work that you've done to characterize off-target editing, because that is so important here.
Question: Andrea Tan - The Goldman Sachs Group, Inc. - Analyst
: And maybe we can jump to your lead programs here. And I was curious just maybe on your comment about the reproductive studies that are
necessary. As you sit now in front of a CTA or IND filing, have you conducted those studies?
Question: Andrea Tan - The Goldman Sachs Group, Inc. - Analyst
: Okay. Well, maybe walk us through, I guess, maybe for HBV, we can start there: where that program stands, the timelines, being able to get to the
clinic, maybe even the approach that you're taking, which is pretty unique.
Question: Andrea Tan - The Goldman Sachs Group, Inc. - Analyst
: Jeff, maybe I'll let you comment here on the approach for this HBV program. What have you seen from the pre-clinical data that makes you so
excited?
Question: Andrea Tan - The Goldman Sachs Group, Inc. - Analyst
: Maybe to that point, what would be the amount of follow up or the durability that you would look to understand that you truly are providing a
functional cure here?
Question: Andrea Tan - The Goldman Sachs Group, Inc. - Analyst
: Great. Maybe we can turn to -- I'm going to skip over PMM today.
Question: Andrea Tan - The Goldman Sachs Group, Inc. - Analyst
: In the interest of time, let's talk about DMD and where that program stands now that you've taken back that from the conclusion of the Lilly Prevail.
Question: Andrea Tan - The Goldman Sachs Group, Inc. - Analyst
: Maybe for people who haven't yet seen your data, just walk us through really quickly what you have seen. What makes you so excited that this
could be more optimal than therapies that are out there?
Question: Andrea Tan - The Goldman Sachs Group, Inc. - Analyst
: No, I was just going to ask if you could put into context the 86% relative to others.
Question: Andrea Tan - The Goldman Sachs Group, Inc. - Analyst
: Maybe in the [last couple of seconds] we have here, things you'd like to leave us with, things you want to make sure that people are focused on
over the next 12 months.
Question: Andrea Tan - The Goldman Sachs Group, Inc. - Analyst
: Perfect. Well, with that, thank you all for joining us.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JUNE 12, 2024 / 2:00PM, DTIL.OQ - Precision BioSciences Inc at Goldman Sachs Global Healthcare Conference
| 
